Related Experiment Video
Updated: Feb 5, 2026

Perspectives on Neuroscience
Published on: July 31, 2007
Current and future perspectives in the management of juvenile idiopathic arthritis
Nicolino Ruperto1, Alberto Martini2
1Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Genoa, Italy.
Insights
Juvenile idiopathic arthritis treatments have advanced, yet many patients remain resistant. Future progress requires better disease classification, novel biomarkers, and targeted anti-inflammatory drugs.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Juvenile idiopathic arthritis (JIA) encompasses various arthritis types in children under 16.
- Significant treatment advancements in JIA over two decades are noted.
- Despite progress, a substantial patient subset exhibits treatment resistance.
Purpose of the Study:
- To outline current challenges and future directions in JIA treatment.
- To identify key areas for improving therapeutic outcomes in JIA patients.
Main Methods:
- Review of legislative initiatives, collaborative networks, and medication availability in JIA treatment.
- Analysis of factors contributing to treatment resistance in JIA.
- Identification of future research and development needs in JIA therapy.
Main Results:
- Treatment resistance persists in a significant proportion of JIA patients.
- Legislative actions, international collaboration, and potent medications have improved JIA care.
- Key areas for advancement include disease phenotyping, biomarker discovery, and clinical trial optimization.
Conclusions:
- Enhanced JIA treatment necessitates precise disease subtyping and identification of predictive biomarkers.
- Streamlined clinical trials and targeted anti-inflammatory therapies are crucial for overcoming treatment resistance.
- Improved collaboration among research institutions, regulatory bodies, and patient groups will accelerate therapeutic innovation in JIA.
Abstract:
The treatment of juvenile idiopathic arthritis has improved tremendously in the past 20 years as a result of appropriate legislative initiatives, large international collaborative networks, and the availability of new potent medications. Despite these considerable advances, a sizable proportion of patients are still resistant to treatment. Further improvement will stem from a better definition of the disease entities under the broad term juvenile idiopathic arthritis (which includes all forms of arthritis with disease onset before the age of 16 years); the discovery of laboratory and imaging biomarkers that could help the tuning of therapy; smoother implementation of clinical trials; more standardised links between academia, regulatory authorities, and patient organisations for the planning of future trials; and the availability of new drugs that selectively target molecules or pathways involved in inflammation.
Related Concept Videos
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality
Social Cognitive Perspective on Personality
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Electrical Current

